VICTORIA ELIZABETH RAGLAND MD
Prescription History 1245894849
Psychiatry & Neurology - Neurology in San Francisco, CA

NPI Status: Active since April 29, 2019

Contact Information

1651 4TH ST
SAN FRANCISCO, CA
ZIP 94158
Phone: (415) 353-2273

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for VICTORIA ELIZABETH RAGLAND MD, an active Neurology specialist practicing in San Francisco, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 55 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 19 claims alone.

Medication Index

No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 29.0
Days Supply 859
CA State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills118.3
Peer Average Days Supply3,428
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $702.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.01

State Avg Cost Per Claim

$51.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Gabapentin

Generic Formulation: GabapentinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 21.0
Days Supply 600
CA State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills134.7
Peer Average Days Supply3,929
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $352.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.00

State Avg Cost Per Claim

$21.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 19
30-Day Fills 27.3
Days Supply 744
CA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills71.3
Peer Average Days Supply2,003
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,104.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.11

State Avg Cost Per Claim

$46.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Primidone

Generic Formulation: PrimidoneSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 264
CA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills55.0
Peer Average Days Supply1,608
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $745.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.12

State Avg Cost Per Claim

$28.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Primidone belongs to a class of drugs known as barbiturate anticonvulsants. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like VICTORIA ELIZABETH RAGLAND MD provides transparency into local medical care patterns within San Francisco, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.